|
|
Blood, 1 December 2004, Vol. 104, No. 12, pp. 3754-3757.
Prepublished online as a Blood First Edition Paper on August 10, 2004; DOI 10.1182/blood-2004-06-2189.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Brief report
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970
Amie S. Corbin,
Ian J. Griswold,
Paul La Rosée,
Kevin W. H. Yee,
Michael C. Heinrich,
Corinne L. Reimer,
Brian J. Druker, and
Michael W. N. Deininger
From the Oregon Health and Science University Cancer Institute, Portland; Howard Hughes Medical Institute; III. Medizinische Universitätsklinik, Fakultät für klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany; Portland Veterans Administration Medical Center, Oregon Health and Science University Cancer Institute; and Millennium Pharmaceuticals, Cambridge, MA.
Oncogenic mutations of the receptor tyrosine kinase KIT occur in gastrointestinal stromal tumors (GISTs), some cases of acute myelogenous leukemia (AML), and systemic mastocytosis (SM). GISTs commonly contain mutations of the KIT juxtamembrane region while SM and AML harbor active site KIT mutations. Imatinib, which potently inhibits juxtamembrane mutants, is effective for the treatment of GISTs but has no activity against active site mutants. We analyzed the inhibitory potential of 2 small molecule inhibitors, MLN518 and PD180970, against different classes of KIT mutants. Both compounds inhibit the growth of cell lines expressing juxtamembrane mutant KIT. MLN518 additionally targets active site mutant cell lines, inhibiting cell proliferation, KIT, and signal transducer and activator of transcription-3 (Stat3) phosphorylation and inducing apoptosis at concentrations that may be clinically achievable. As phase 1 clinical trials of MLN518 in AML have shown little toxicity, our data suggest MLN518 is a promising candidate for the treatment of SM or AML with KIT mutations.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Fernandez, A. Sanguino, Z. Peng, A. Crespo, E. Ozturk, X. Zhang, S. Wang, W. Bornmann, and G. Lopez-Berestein
Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target
Am. Assoc. Cancer Res. Educ. Book,
April 12, 2008;
2008(1):
589 - 599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, S. Verstovsek, and A. Pardanani
How we diagnose and treat WHO-defined systemic mastocytosis in adults
Haematologica,
January 1, 2008;
93(1):
6 - 9.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Todd, S. M. Haider, G. N. Parkinson, and S. Neidle
Sequence occurrence and structural uniqueness of a G-quadruplex in the human c-kit promoter
Nucleic Acids Res.,
September 27, 2007;
35(17):
5799 - 5808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Fernandez, A. Sanguino, Z. Peng, A. Crespo, E. Ozturk, X. Zhang, S. Wang, W. Bornmann, and G. Lopez-Berestein
Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target
Cancer Res.,
May 1, 2007;
67(9):
4028 - 4033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Xiang, F. Kreisel, J. Cain, A. Colson, and M. H. Tomasson
Neoplasia Driven by Mutant c-KIT Is Mediated by Intracellular, Not Plasma Membrane, Receptor Signaling
Mol. Cell. Biol.,
January 1, 2007;
27(1):
267 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pan, A. Quintas-Cardama, H. M. Kantarjian, C. Akin, T. Manshouri, P. Lamb, J. E. Cortes, A. Tefferi, F. J. Giles, and S. Verstovsek
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
Blood,
January 1, 2007;
109(1):
315 - 322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gabillot-Carre, Y. Lepelletier, M. Humbert, P. de Sepuvelda, N. B. Hamouda, J. P. Zappulla, R. Liblau, A. Ribadeau-Dumas, F. Machavoine, S. Letard, et al.
Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells
Blood,
August 1, 2006;
108(3):
1065 - 1072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. P. Shah, F. Y. Lee, R. Luo, Y. Jiang, M. Donker, and C. Akin
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
Blood,
July 1, 2006;
108(1):
286 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Schittenhelm, S. Shiraga, A. Schroeder, A. S. Corbin, D. Griffith, F. Y. Lee, C. Bokemeyer, M. W.N. Deininger, B. J. Druker, and M. C. Heinrich
Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies
Cancer Res.,
January 1, 2006;
66(1):
473 - 481.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kobayashi, H. Ji, Y. Yuza, M. Meyerson, K.-K. Wong, D. G. Tenen, and B. Halmos
An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor
Cancer Res.,
August 15, 2005;
65(16):
7096 - 7101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Corless, A. Schroeder, D. Griffith, A. Town, L. McGreevey, P. Harrell, S. Shiraga, T. Bainbridge, J. Morich, and M. C. Heinrich
PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib
J. Clin. Oncol.,
August 10, 2005;
23(23):
5357 - 5364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Carter, L. M. Wodicka, N. P. Shah, A. M. Velasco, M. A. Fabian, D. K. Treiber, Z. V. Milanov, C. E. Atteridge, W. H. Biggs III, P. T. Edeen, et al.
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
PNAS,
August 2, 2005;
102(31):
11011 - 11016.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Corbin, S. Demehri, I. J. Griswold, Y. Wang, C. A. Metcalf III, R. Sundaramoorthi, W. C. Shakespeare, J. Snodgrass, S. Wardwell, D. Dalgarno, et al.
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit
Blood,
July 1, 2005;
106(1):
227 - 234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
